GlassScriptPhysician profile
Ashley Marie Patterson
NPI 1700457645
$5,257.73
in general payments reported to CMS, 2019-2025
25 companies · $2,153 in 2025
The $2,153 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $228 · 2023: $786 · 2024: $2,090 · 2025: $2,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,029.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,053.26 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $855.95 | 2022-2025 | |
| Pfizer INC. | $750.43 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $546.11 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $454.83 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $310.56 | 2023-2025 | Evenity, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.75 | 2024-2025 | Jardiance |
| Dexcom, INC. | $176.63 | 2022-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $132.61 | 2024-2025 | Korlym |
| Corium, LLC | $114.98 | 2023-2025 | Azstarys |
| Novartis Pharmaceuticals Corporation | $94.81 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.67 | 2024-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $80.25 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.80 | 2024-2025 | Trintellix |
| Exact Sciences Corporation | $50.83 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $49.94 | 2025 | Symbravo |
| Tris Pharma INC | $37.02 | 2023 | Dyanavel Xr |
| Philips North America LLC | $35.39 | 2025 | Extended Holter |
| Esperion Therapeutics, INC. | $32.86 | 2023-2024 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.55 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $25.54 | 2022-2024 | Trelegy Ellipta |
| Azurity Pharmaceuticals, INC. | $19.67 | 2025 | |
| Xeris Pharmaceuticals, INC. | $17.69 | 2024 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $17.43 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $15.17 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.